STOCKS / Finance

Nektar Hurting Shorts With Positive Results From NKTR-181 Study

From Technicals
March 20, 2017 - 10:52am
Nektar Therapeutics (NASDAQ: NKTR) shares are trading higher by $5.00 (33 percent) at $20.50 in Monday's session. The catalyst for the rally is that its study for NKTR-181 has met its primary and secondary endpoints in Phase 3 Summit-07 study for chronic pain. After a $3.00 ...Full story available on Benzinga.com


Continue reading this article »